Interactions on record — worth a quick check against your medications. Based on 6 of 9 ingredients. Check your meds →
Dietary supplement

Fresh Mouth Ingredients & Drug Interactions

by Global Healing Center

Liquid Category: Other Combinations
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Fresh Mouth is a dietary supplement by Global Healing Center with 9 active ingredients. Its ingredients are commonly taken for irritable bowel syndrome (ibs), indigestion and gas, nausea.Based on those ingredients, 1,486 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are organic Sage, organic Clove, organic Eucalyptus. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Fresh Mouth by Global Healing Center

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 9 active ingredients.
  • “Proprietary Blend” is a proprietary blend — the label gives one combined amount (0.20 mL) without saying how much of each component you get.

Fresh Mouth is a liquid formula with nine ingredients. The active components are peppermint (listed twice — once as the herb and once as essential oil), menthol, eucalyptus, sage, clove, spearmint, pine, and myrrh.

These are aromatics and traditional mouth-care botanicals chosen for their flavor and freshening properties. The formula also contains vegetable glycerin and purified water as inactive ingredients (the liquid base).

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use.

Why this rating?
  • The label markets this product for: oral health formula.
  • We looked for evidence on: Canker sores, Dental peri-implantitis, Dental plaque, Dry mouth, Gingivitis, Halitosis — and 4 related terms.
  • The closest evidence on file: Clove is rated "Insufficient Reliable Evidence To Rate" for Dental plaque (Natural Medicines).
  • Also on file: Clove is rated "Insufficient Reliable Evidence To Rate" for Gingivitis, Oral mucositis, Halitosis.
  • Also on file: Sage is rated "Insufficient Reliable Evidence To Rate" for Herpes labialis (cold sores), Dental plaque, Dry mouth.

The data we hold shows effectiveness ratings for only some of these ingredients, and most lack solid proof. Peppermint has the strongest evidence — it's likely effective for irritable bowel syndrome (IBS) and possibly effective for indigestion and nausea from chemotherapy.

Sage is possibly effective for menopausal symptoms, high cholesterol, and cognitive function. Clove is possibly effective for ventilator-associated pneumonia, though that's a clinical condition unlikely relevant to a mouth rinse.

Eucalyptus, spearmint, and myrrh all show insufficient evidence in the data we hold for their marketed uses. Because this is a fresh-breath product, the actual evidence for "freshening" breath or oral health isn't established in our data — we can only speak to what the individual botanicals have been studied for.

The evidence, ingredient by ingredient Peppermint Eucalyptus Sage Clove Spearmint Myrrh

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 6 of the 6 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 6 of 6.
  • General safety write-ups exist for 6 of 6.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Peppermint and clove are generally well tolerated when used as food or in diluted amounts, though concentrated peppermint oil can irritate the mouth and, in rare cases, cause burns or allergic reactions (lip swelling, throat tightness). Eucalyptus oil is safe in small doses for inhalation or diluted topical use but can be poisonous if swallowed undiluted — even a teaspoon of the pure oil may cause serious toxicity in children.

Sage is fine as a culinary spice but should be avoided in medicinal amounts during pregnancy because of thujone content. Spearmint is well tolerated as food or tea.

Myrrh has not been well studied for oral safety, though short-term topical or rinse use is traditionally considered acceptable. Common side effects from these ingredients include mild mouth or throat burning, nausea, and, rarely, allergic skin reactions.

One case of anaphylaxis from peppermint has been reported.

Side effects, ingredient by ingredient Peppermint Eucalyptus Sage Clove Spearmint Myrrh

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 6 of the 6 matched ingredients can interact with medications — Clove, Sage, Myrrh, Eucalyptus, Peppermint, among others.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; seizure medications; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 1,487 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before using Fresh Mouth, double-check with your doctor or pharmacist if you take medications broken down by liver enzymes, especially CYP3A4 substrates (like certain blood pressure and heart drugs); blood-sugar drugs; blood thinners like warfarin; immune suppressants like cyclosporine; sedatives or CNS depressants; estrogen or hormone therapy; or drugs for attention or wakefulness. Most interactions are theoretical, but peppermint's effect on CYP3A4 has been shown in clinical trials.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.

Fresh Mouth is a botanical mouth rinse whose ingredients have modest to no established evidence for oral-health benefits. The real concern is medication interactions — peppermint, eucalyptus, sage, clove, spearmint, and myrrh can theoretically raise levels of many medications your liver metabolizes, and one interaction (peppermint with CYP3A4 drugs) has been confirmed in people.

If you take any prescription drugs, especially for blood pressure, heart rhythm, blood thinning, diabetes, or sleep, check with your doctor or pharmacist before using this product. Otherwise, as an occasional mouth rinse in small amounts, it's generally well tolerated.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 7 of 9 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jul 24, 2019.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Fresh Mouth, straight from the product label.

Brand Global Healing Center
Barcode (UPC) 718122403554
Net contents 1 fl. Oz.; 29.6 mL
Market status On market
Date entered into DSLD Jul 24, 2019
DSLD ID 204392
Product type Other Combinations
Supplement form Liquid
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Adult (18 - 50 Years), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Fresh Mouth by Global Healing Center, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Spray(s)
Maximum serving Sizes:
2 Spray(s)
Servings per container
148
UPC/BARCODE
718122403554
IngredientAmount% DV
Peppermint0 NP--
Menthol0 NP--
Proprietary Blend0.2 mL--
organic Eucalyptus0 NP--
Peppermint essential Oil0 NP--
organic Sage0 NP--
organic Clove0 NP--
Spearmint0 NP--
organic Pine0 NP--
wildcrafted Myrrh0 NP--

Other ingredients: USP Kosher certified Vegetable Glycerin, purified Water

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions

Suggested use Shake bottle well. Spray 2-3 times in mouth as needed and swallow.

Precautions

Warning: Keep out of reach of children.

Consult your healthcare provider before taking if you are pregnant or nursing, or have any other medical concerns.

FDA Disclaimer Statement

These statements have not been evaluated by the Food an Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

General Statements

Since 1998

Oral health formula

FDA Statement of Identity

All Natural Dietary Supplement

Seals/Symbols

GMO Free

Vegan

Made in the USA

Gluten Free

No Animal Testing

Formulation

GMO Free

Vegan

Gluten Free

See for yourself

Fresh Mouth by Global Healing Center label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Fresh Mouth by Global Healing Center

These are the 9 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Spray(s) Dosage formLiquid Servings per container148 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Blend

0.2 mL per serving

Other (inactive) ingredients: USP Kosher certified Vegetable Glycerin, Purified Water. These complete the product’s ingredient list but are not active constituents.

Interaction report

Fresh Mouth by Global Healing Center Drug Interactions

Want to check YOUR meds against Fresh Mouth?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,486Drugs
1,437 Moderate 49 Minor

Ingredients driving the most interactions

organic Sage 1,296
Spearmint 579

Each ingredient & the kinds of drugs it affects

For each ingredient in Fresh Mouth with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

organic Sage14 drug types · 1,296 drugs

Anticholinergic Drugs

Theoretically, sage might decrease the clinical effects of anticholinergic drugs.
In vitro evidence suggests that common sage (Salvia officinalis) and Spanish sage (Salvia lavandulaefolia) can inhibit acetylcholinesterase and might increase acetylcholine levels.

Likelihood Possible Evidence D
Anticonvulsants

Theoretically, sage might interfere with the clinical effects of anticonvulsant drugs.
Some species of sage can cause convulsions when consumed in large quantities.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, taking sage with antidiabetes drugs might increase the risk of hypoglycemia.
In patients with polycystic ovary syndrome (PCOS) or inadequately controlled type 2 diabetes, common sage (Salvia officinalis) has demonstrated hypoglycemic activity. However, other clinical research in patients with inadequately controlled type 2 diabetes shows that common sage extract does not lower fasting blood glucose levels.

Likelihood Possible Evidence B
Antihypertensive Drugs

Theoretically, sage might increase or decrease the effects of antihypertensive drugs.
Animal research suggests that common sage (Salvia officinalis) can cause prolonged blood pressure reduction. However, clinical research suggests that Spanish sage (Salvia lavandulaefolia) can increase blood pressure in some people with hypertension. Until more is known, use with caution.

Likelihood Possible Evidence D
Benzodiazepines

Theoretically, taking sage might increase the sedative and adverse effects of benzodiazepines.
In vitro evidence suggests that certain components of common sage (Salvia officinalis) can bind to benzodiazepine receptors. This effect has not been reported in humans.

Likelihood Possible Evidence D
Cholinergic Drugs

Theoretically, sage might have additive effects when used with cholinergic drugs.
In vitro evidence suggests that common sage (Salvia officinalis) and Spanish sage (Salvia lavandulaefolia) can inhibit acetylcholinesterase and might increase acetylcholine levels.

Likelihood Possible Evidence D
Cns Depressants

Theoretically, taking sage might increase the sedative and adverse effects of CNS depressants.
Some constituents of sage have CNS depressant activity.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, sage might increase the levels and clinical effects of drugs metabolized by CYP2C19.
In vitro evidence suggests that aqueous extracts of sage can inhibit CYP2C19. So far, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, sage might increase the levels and clinical effects of drugs metabolized by CYP2C9.
In vitro evidence suggests that aqueous extracts of sage can inhibit CYP2C9. So far, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, sage might increase the levels and clinical effects of drugs metabolized by CYP2D6.
In vitro evidence suggests that aqueous extracts of sage can inhibit CYP2D6. So far, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2E1 (Cyp2E1) Substrates

Theoretically, sage might decrease the levels and clinical effects of drugs metabolized by CYP2E1.
Animal research suggests that drinking common sage (Salvia officinalis) tea increases the expression of CYP2E1. So far, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, sage might increase the levels and clinical effects of drugs metabolized by CYP3A4.
In vitro evidence suggests that aqueous extracts of sage can inhibit CYP3A4. So far, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Estrogens

Theoretically, sage might interfere with hormone therapy.
In vitro evidence suggests that geraniol, a constituent of Spanish sage (Salvia lavandulaefolia), exerts estrogenic activity. The clinical significance of this effect is unclear.

Likelihood Possible Evidence D
P-Glycoprotein Substrates

Theoretically, sage might increase levels of drugs transported by P-glycoprotein.
In vitro research suggests that common sage (Salvia officinalis) can inhibit the multi-drug transporter protein, P-glycoprotein. This effect has not been reported in humans.

Likelihood Possible Evidence D

organic Clove7 drug types · 977 drugs

Antidiabetes Drugs

Theoretically, concomitant use of clove extracts with antidiabetes drugs might increase the risk of hypoglycemia.
Clinical and laboratory research suggest that polyphenol extracts from clove flower buds might lower blood glucose levels. Dosing adjustments for insulin or oral hypoglycemic agents may be necessary when taken with clove. Monitor blood glucose levels closely.

Likelihood Possible Evidence D
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, concomitant use of clove may increase levels of drugs metabolized by CYP1A2.
In vitro research shows that eugenol, the principal constituent of clove, can inhibit CYP1A2 in a dose-dependent manner,. This effect has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, concomitant use of clove may increase levels of drugs metabolized by CYP2C9.
In vitro research shows that eugenol, the principal constituent of clove, inhibits CYP2C9 in a dose-dependent manner. This effect has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, concomitant use of clove may increase levels of drugs metabolized by CYP2D6.
In vitro research shows that eugenol, the principal constituent of clove, can inhibit CYP2D6 in a dose-dependent manner. This effect has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, concomitant use of clove may increase levels of drugs metabolized by CYP3A4.
In vitro research shows that eugenol, the principal constituent of clove, can inhibit CYP3A4 in a dose-dependent manner. This effect has not been reported in humans.

Likelihood Possible Evidence D
Anticoagulant/Antiplatelet Drugs

Theoretically, clove oil may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.
Laboratory research suggests that eugenol, a constituent of clove, has antiplatelet activity. This interaction has not been reported in humans.

Likelihood Unlikely Evidence D
Ibuprofen (Advil, Others)

Theoretically, topical application of clove oil with ibuprofen might increase the absorption and side effects of topical ibuprofen.
Laboratory research shows that topical application of clove oil increases the absorption of topical ibuprofen. This interaction has not been reported in humans.

Likelihood Possible Evidence D

organic Eucalyptus7 drug types · 878 drugs

Amphetamines

Theoretically, inhaling eucalyptol may reduce the effectiveness of amphetamines.
Animal research suggests that inhaling eucalyptol may reduce the levels of amphetamines in the blood.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, eucalyptus leaf might increase the risk of hypoglycemia.
Animal research suggests that eucalyptus leaf might have hypoglycemic activity, and might have additive effects when used with antidiabetes drugs.

Likelihood Possible Evidence D
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, eucalyptus might increase the levels of CYP1A2 substrates.
In vitro research suggests that eucalyptus oil might inhibit CYP1A2, although this has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, eucalyptus might increase the levels of CYP2C19 substrates.
In vitro research suggests that eucalyptus oil might inhibit CYP2C19, although this has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, eucalyptus might increase the levels of CYP2C9 substrates.
In vitro research suggests that eucalyptus oil might inhibit CYP2C9, although this has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, eucalyptus might increase the levels of CYP3A4 substrates.
In vitro research suggests that eucalyptus oil might inhibit CYP3A4, although this has not been reported in humans.

Likelihood Possible Evidence D
Pentobarbital (Nembutal)

Theoretically, inhaling eucalyptol might reduce the effectiveness of pentobarbital.
Animal research suggests that inhaling eucalyptol reduces the level of pentobarbital that reaches the brain.

Likelihood Possible Evidence D

Peppermint5 drug types · 796 drugs

Cyclosporine (Neoral, Sandimmune)

Theoretically, peppermint oil might increase the levels and adverse effects of cyclosporine.
In animal research, peppermint oil inhibits cyclosporine metabolism and increases cyclosporine levels. Inhibition of cytochrome P450 3A4 (CYP3A4) may be partially responsible for this interaction. An interaction between peppermint oil and cyclosporine has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, peppermint might increase the levels of CYP2C19 substrates.
In vitro research shows that peppermint oil inhibits CYP2C19. So far, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, peppermint might increase the levels of CYP2C9 substrates.
In vitro research shows that peppermint oil inhibits CYP2C9. So far, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, peppermint might increase the levels of CYP3A4 substrates.
Clinical research in healthy volunteers shows that a single dose of peppermint oil 600 mg inhibits CYP3A4 enzymes and increases the AUC of felodipine, a CYP3A4 substrate. However, in vitro research suggests that peppermint oil only inhibits CYP3A4 at very high concentrations.

Likelihood Possible Evidence B
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, peppermint might increase the levels of CYP1A2 substrates.
In vitro and animal research shows that peppermint oil and peppermint leaf inhibit CYP1A2. However, in clinical research, peppermint tea did not significantly affect the metabolism of caffeine, a CYP1A2 substrate. It is possible that the 6-day duration of treatment may have been too short to identify a difference.

Likelihood Possible Evidence B

Spearmint2 drug types · 579 drugs

Cns Depressants

Theoretically, spearmint might alter the sedative effects of CNS depressants.
Animal research suggests that (-)-carvone, a major constituent of spearmint, has sedative effects. However, in humans, chewing spearmint-flavored gum induced arousal effects.

Likelihood Possible Evidence D
Hepatotoxic Drugs

Theoretically, high doses of spearmint might increase the risk of liver damage when taken with hepatotoxic drugs.
Animal research suggests that drinking spearmint tea for 30 days can increase markers of liver damage, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and cause liver degeneration and necrosis, in a dose-dependent manner. This effect has not been reported in humans.

Likelihood Possible Evidence D

wildcrafted Myrrh2 drug types · 88 drugs

Antidiabetes Drugs

Theoretically, myrrh might increase the risk of hypoglycemia when taken with antidiabetes drugs.
In vitro and animal research suggests that myrrh has hypoglycemic effects.

Likelihood Possible Evidence D
Warfarin (Coumadin)

Theoretically, myrrh might decrease the effectiveness of warfarin.
In one case, a patient who was previously stable on warfarin had a significant decline in international normalized ratio (INR) following consumption of an aqueous extract of myrrh.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Fresh Mouth, from the product label.

Global Healing Center

See all Global Healing Center products
Name
Global Healing Center, LP.
City
Houston
State
Texas
ZipCode
77018
Phone Number
1.800.476.0016
Web Address
www.globalhealingcenter.com
Pharmacist Counseling Corner

Fresh Mouth by Global Healing Center: Common Questions

Does Fresh Mouth by Global Healing Center interact with any medications?
Yes. Based on its ingredients, Fresh Mouth has a known interaction with 1,486 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Fresh Mouth contains 9 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is this safe to use if I'm pregnant?
Peppermint and clove are likely safe in pregnancy; spearmint is also likely safe. However, sage should be avoided in medicinal amounts during pregnancy, and myrrh is considered likely unsafe. Because this product contains both, there isn't enough data to know whether the mix as a whole is safe in pregnancy — talk with your doctor or midwife before using it.
Is this safe while breastfeeding?
Peppermint, clove, and spearmint are likely safe while nursing. Sage is possibly unsafe, and we don't have enough data on myrrh. If you're breastfeeding, check with your doctor or pharmacist before using this product.
What should I do if I swallow this by accident?
Fresh Mouth is meant to be rinsed in your mouth and spit out, not swallowed. If you or a child swallows a significant amount, the eucalyptus in particular could cause harm — call Poison Control or your doctor right away, especially for children.
Can I use this if I have asthma?
One person with asthma reported worsening symptoms after inhaling eucalyptus. If you have asthma or a history of lung sensitivity, mention this product to your doctor before using it, since it will release vapors when you rinse.
Will this freshen my breath?
The product contains traditional mouth-freshening botanicals like peppermint, spearmint, clove, and myrrh, and these are commonly used for flavor and aroma. However, we don't hold clinical evidence specifically for this product's ability to freshen breath — that claim isn't studied in the data we have.
What are the most common side effects?
The most common side effects from these ingredients are mild — mouth or throat burning, tingling, or dryness. Nausea, abdominal discomfort, or diarrhea can occur if the product is swallowed. Allergic reactions, including skin rashes or throat swelling, are rare but have been reported with peppermint and spearmint.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Fresh Mouth is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Fresh Mouth label
Go deeper

The Full Monographs Behind Fresh Mouth’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Peppermint

Interacts with 796 drugs

Peppermint is a popular herb with the best evidence supporting enteric-coated peppermint oil for easing IBS symptoms. It is generally well tolerated for most adults, but it can cause heartbu...

Read the full Peppermint monograph →
Herb & supplement monograph

Eucalyptus

Interacts with 878 drugs

Eucalyptus is best known for its strong-smelling oil used in vapor rubs, inhalants, and lozenges to ease coughs and congestion. It may provide mild, short-term relief of cold symptoms, but t...

Read the full Eucalyptus monograph →
Herb & supplement monograph

Sage

Interacts with 1,296 drugs

Sage is a common kitchen herb that is generally safe in food amounts and is traditionally used for sore throats, digestion, sweating, and memory. Some early research is encouraging for sore...

Read the full Sage monograph →
Herb & supplement monograph

Clove

Interacts with 977 drugs

Clove is a common cooking spice that is also used in traditional medicine, especially as a topical numbing agent for tooth pain thanks to its main compound, eugenol. Food amounts are general...

Read the full Clove monograph →
Herb & supplement monograph

Spearmint

Interacts with 579 drugs

Spearmint is a common culinary mint that is generally safe in food and tea amounts. Early research suggests possible benefits for digestion, mild hormone-related issues (such as excess facia...

Read the full Spearmint monograph →
Herb & supplement monograph

Myrrh

Interacts with 88 drugs

Myrrh is a fragrant gum resin from Commiphora trees that has long been used in mouthwashes, throat remedies, and skin care. Modern evidence for most of its uses is limited and comes mostly f...

Read the full Myrrh monograph →
Sources

Sources & How We Checked

Fresh Mouth's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 145 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Peppermint 41 references
  1. Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-8. PubMed
  2. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-5. PubMed
  3. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 2001;138:125-8. PubMed
  4. Madisch A, Heydenreich CJ, Wieland V, et al. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled, double-blind equivalence study. Arzneimittel
  5. May B, Kuntz HD, Kieser M, Kohler S. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittelforschung 1996;46:1149-53.
  6. Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res 2000;14:20-3. DOI
  7. Morton CA, Garioch J, Todd P, et al. Contact sensitivity to menthol and peppermint in patients with intra-oral symptoms. Contact Dermatitis 1995;32:281-4. PubMed
  8. May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000;14:1671-7. PubMed
  9. Nash P, Gould SR, Bernardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. Br J Clin Pract 1986;40:292-3. DOI
  10. Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J 1979;2:835-6. PubMed
  11. Davies SJ, Harding LM, Baranowski AP. A novel treatment of postherpetic neuralgia using peppermint oil. Clin J Pain 2002;18:200-2. PubMed
  12. Weston CF. Anal burning and peppermint oil. Postgrad Med J 1987;63:717. PubMed
  13. Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002;72:247-55. PubMed
  14. Wacher VJ, Wong S, Wong HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. J Pharm Sci 2002;91:77-90.
  15. Lawson MJ, Knight RE, Tran K, et al. Failure of enteric-coated peppermint oil in the irritable bowel syndrome: a randomized double-blind crossover study. J Gastroenterol Hepatol 1988;3:235-8. DOI
  16. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;1 PubMed
  17. Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001;53:1323-9. PubMed
  18. Rogers SN, Pahor AL. A form of stomatitis induced by excessive peppermint consumption. Dent Update 1995;22:36-7.
  19. Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007;39:530-6. PubMed
  20. Moghadam BK, Gier R, and Thurlow T. Extensive oral mucosal ulcerations caused by misuse of a commercial mouthwash. Cutis 1999;64:131-134.
  21. Andersen, K. E. Contact allergy to toothpaste flavors. Contact Dermatitis 1978;4(4):195-198. PubMed
  22. Barnard, D. R. Repellency of essential oils to mosquitoes (Diptera: Culicidae). J Med Entomol. 1999;36(5):625-629. PubMed
  23. Tamir, S., Davidovich, Z., Attal, P., and Eliashar, R. Peppermint oil chemical burn. Otolaryngol.Head Neck Surg. 2005;133(5):801-802. PubMed
  24. Kalavala, M., Hughes, T. M., Goodwin, R. G., Anstey, A. V., and Stone, N. M. Allergic contact dermatitis to peppermint foot spray. Contact Dermatitis 2007;57(1):57-58. PubMed
  25. Vermaat, H., van Meurs, T., Rustemeyer, T., Bruynzeel, D. P., and Kirtschig, G. Vulval allergic contact dermatitis due to peppermint oil in herbal tea. Contact Dermatitis 2008;58(6):364-365. PubMed
  26. Merat, S., Khalili, S., Mostajabi, P., Ghorbani, A., Ansari, R., and Malekzadeh, R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig.Dis.Sci. 2010;55(5):1385-1390. PubMed
  27. Tran, A., Pratt, M., and DeKoven, J. Acute allergic contact dermatitis of the lips from peppermint oil in a lip balm. Dermatitis 2010;21(2):111-115. DOI
  28. Hitz, Lindenmuller, I and Lambrecht, J. T. Oral care. Curr Probl.Dermatol 2011;40:107-115.
  29. Shavakhi, A., Ardestani, S. K., Taki, M., Goli, M., and Keshteli, A. H. Premedication with peppermint oil capsules in colonoscopy: a double blind placebo-controlled randomized trial study. Acta Gastroenterol Belg 2012;75(3):349-353.
  30. Lech, Y., Olesen, K. M., Hey, H., Rask-Pedersen, E., Vilien, M., and Ostergaard, O. [Treatment of irritable bowel syndrome with peppermint oil. A double- blind study with a placebo]. Ugeskr.Laeger 10-3-1988;150(40):2388-2389.
  31. Parys, B. T. Chemical burns resulting from contact with peppermint oil mar: a case report. Burns Incl.Therm.Inj. 1983;9(5):374-375. PubMed
  32. Bayat R, Borici-Mazi R. A case of anaphylaxis to peppermint. Allergy Asthma Clin Immunol. 2014;10(1):6. PubMed
  33. Rich G, Shah A, Koloski N, et al. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol Motil 2 PubMed
  34. Douros A, Bronder E, Andersohn F, et al. Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. Int J Mol Sci 2016;17(1). PubMed
  35. Begas E, Tsioutsiouliti A, Kouvaras E, et al. Effects of peppermint tea consumption on the activities of CYP1A2, CYP2A6, Xanthine Oxidase, N-acetyltranferase-2 and UDP-glucuronosyltransferases-1A1/1A6 in healthy volunteers. Food Chem Toxicol 2017;100:80-9 PubMed
  36. Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci 2016;61(2):560-71. PubMed
  37. Elsaie LT, El Mohsen AM, Ibrahim IM, Mohey-Eddin MH, Elsaie ML. Effectiveness of topical peppermint oil on symptomatic treatment of chronic pruritus. Clin Cosmet Investig Dermatol 2016;9:333-8. PubMed
  38. Wu J, Xu R, Zhan R, et al. Effective symptomatic treatment for severe and intractable pruritus associated with severe burn-induced hypertrophic scars: A prospective, multicenter, controlled trial. Burns 2016;42(5):1059-66. PubMed
  39. Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology. 2020;158(1):123-136. PubMed
  40. Nee J, Ballou S, Kelley JM, et al. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. Am J Gastroenterol 2021;116(11):2279-2285. PubMed
  41. Ingrosso MR, Ianiro G, Nee J, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther 2022;56(6):932-41. PubMed

See these in context on the Peppermint monograph →

Eucalyptus 23 references
  1. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  2. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;1 PubMed
  3. De Vincenzi M, Silano M, De Vincenzi A, et al. Constituents of aromatic plants: eucalyptol. Fitoterapia 2002;73:269-75. PubMed
  4. Gray AM, Flatt PR. Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) are associated with pancreatic and extra-pancreatic effects in mice. J Nutr 1998;128:2319-23. PubMed
  5. Whitman BW, Ghazizadeh H. Eucalyptus oil: therapeutic and toxic aspects of pharmacology in humans and animals. J Paediatr Child Health 1994;30:190-1. PubMed
  6. Barker SC and Altman PM. An ex vivo, assessor blind, randomised, parallel group, comparative efficacy trial of the ovicidal activity of three pediculicides after a single application--melaleuca oil and lavender oil, eucalyptus oil and lemon tea tree oil,
  7. Vilaplana, J. and Romaguera, C. Allergic contact dermatitis due to eucalyptol in an anti-inflammatory cream. Contact Dermatitis 2000;43(2):118.
  8. Juergens, U. R. [Reducing the need for cortisone. Does eucalyptus oil work in asthma? (interview by Brigitte Moreano]. MMW.Fortschr Med 3-29-2001;143(13):14.
  9. Tascini, C., Ferranti, S., Gemignani, G., Messina, F., and Menichetti, F. Clinical microbiological case: fever and headache in a heavy consumer of eucalyptus extract. Clin Microbiol.Infect. 2002;8(7):437, 445-437, 446. PubMed
  10. Galdi, E., Perfetti, L., Calcagno, G., Marcotulli, M. C., and Moscato, G. Exacerbation of asthma related to Eucalyptus pollens and to herb infusion containing Eucalyptus. Monaldi Arch.Chest Dis. 2003;59(3):220-221.
  11. Spoerke, D. G., Vandenberg, S. A., Smolinske, S. C., Kulig, K., and Rumack, B. H. Eucalyptus oil: 14 cases of exposure. Vet Hum.Toxicol 1989;31(2):166-168.
  12. Jori, A., Bianchetti, A., Prestini, P. E., and Gerattini, S. Effect of eucalyptol (1,8-cineole) on the metabolism of other drugs in rats and in man. Eur.J Pharmacol 1970;9(3):362-366. PubMed
  13. Tibballs, J. Clinical effects and management of eucalyptus oil ingestion in infants and young children. Med J Aust 8-21-1995;163(4):177-180. PubMed
  14. Webb, N. J. and Pitt, W. R. Eucalyptus oil poisoning in childhood: 41 cases in south-east Queensland. J Paediatr.Child Health 1993;29(5):368-371. PubMed
  15. Gyldenløve M, Menné T, Thyssen JP. Eucalyptus contact allergy. Contact Dermatitis. 2014;71(5):303-304. PubMed
  16. Higgins C, Palmer A, Nixon R. Eucalyptus oil: contact allergy and safety. Contact Dermatitis. 2015;72(5):344-346. PubMed
  17. de Groot AC, Schmidt E. Eucalyptus oil and tea tree oil. Contact Dermatitis. 2015;73(6):381-386. PubMed
  18. Greive KA, Barnes TM. The efficacy of Australian essential oils for the treatment of head lice infestation in children: A randomised controlled trial. Australas J Dermatol. 2018;59(2):e99-e105. PubMed
  19. Paulsen E, Thormann H, Vestergaard L. Eucalyptus species as a cause of airborne allergic contact dermatitis. Contact Dermatitis. 2018;78(4):301-303.
  20. Mathew T, John SK, Kamath V, et al. Essential oil related seizures (EORS): A multi-center prospective study on essential oils and seizures in adults. Epilepsy Res. 2021;173:106626. PubMed
  21. Dudipala SC, Mandapuram P, Ch LK. Eucalyptus Oil-Induced Seizures in Children: Case Reports and Review of the Literature. J Neurosci Rural Pract 2021;12(1):112-115. PubMed
  22. Panda PK, Sharawat IK, Panda P, Dawman L, Kasinathan A. Clinico-laboratory characteristics and outcome of patients with eucalyptus oil-induced/provoked seizures: A case series and systematic review of the published patients. Trop Doct 2021;51(4):518-522. PubMed
  23. Sai Chandar D, Prashanthi M, Laxman Kumar C, Amith Kumar C. Eucalyptus Oil-Induced Seizures in Children: A Single-Center Prospective Study. Cureus 2021;13(3):e14109. PubMed

See these in context on the Eucalyptus monograph →

Sage 27 references
  1. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  2. Todorov S, Philianos S, Petkov V, et al. Experimental pharmacological study of three species from genus Salvia. Acta Physiol Pharmacol (Bulg) 1984;10:13-20.
  3. Perry NS, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav 2003;75:651-9.. PubMed
  4. Saller R, Buechi S, Meyrat R, Schmidhauser C. Combined herbal preparation for topical treatment of Herpes labialis. Forsch Komplementarmed Klass Naturheilkd 2001;8:373-82. PubMed
  5. Akhondzadeh S, Noroozian M, Mohammadi M, et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003;28:53-9.
  6. Perry NB, Anderson RE, Brennan NJ, et al. Essential oils from dalmatian sage (Salvia officinalis l.): variations among individuals, plant parts, seasons, and sites. J Agric Food Chem 1999;47:2048-54..
  7. Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003;10:334-42.. PubMed
  8. Burkhard PR, Burkhardt K, Haenggeli CA, Landis T. Plant-induced seizures: reappearance of an old problem. J Neurol 1999;246:667-70. PubMed
  9. Bommer S, Klein P, Suter A. First time proof of sage's tolerability and efficacy in menopausal women with hot flushes. Adv Ther 2011;28:490-500. PubMed
  10. Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol. 2007 Nov;101:350-8.
  11. Orhan, I., Kartal, M., Kan, Y., and Sener, B. Activity of essential oils and individual components against acetyl- and butyrylcholinesterase. Z.Naturforsch.C. 2008;63(7-8):547-553.
  12. Perry, N. S., Houghton, P. J., Theobald, A., Jenner, P., and Perry, E. K. In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 2000;52(7):895-902.
  13. Perry, N. S., Houghton, P. J., Sampson, J., Theobald, A. E., Hart, S., Lis-Balchin, M., Hoult, J. R., Evans, P., Jenner, P., Milligan, S., and Perry, E. K. In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's diseas
  14. Futrell, J. M. and Rietschel, R. L. Spice allergy evaluated by results of patch tests. Cutis 1993;52(5):288-290.
  15. Kavvadias, D., Monschein, V., Sand, P., Riederer, P., and Schreier, P. Constituents of sage (Salvia officinalis) with in vitro affinity to human brain benzodiazepine receptor. Planta Med. 2003;69(2):113-117.
  16. Savelev, S. U., Okello, E. J., and Perry, E. K. Butyryl- and acetyl-cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother Res 2004;18(4):315-324.
  17. Kennedy, D. O., Pace, S., Haskell, C., Okello, E. J., Milne, A., and Scholey, A. B. Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery. Neuropsychopharmacology 2006;31(4):84 PubMed
  18. Hubbert, M., Sievers, H., Lehnfeld, R., and Kehrl, W. Efficacy and tolerability of a spray with Salvia officinalis in the treatment of acute pharyngitis - a randomised, double-blind, placebo-controlled study with adaptive design and interim analysis. Eur
  19. Lima, C. F., Fernandes-Ferreira, M., and Pereira-Wilson, C. Drinking of Salvia officinalis tea increases CCl(4)-induced hepatotoxicity in mice. Food Chem.Toxicol. 2007;45(3):456-464.
  20. Hellum, B. H. and Nilsen, O. G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol. 2008;102(5):466-475.
  21. Mayer, E., Gescheidt-Shoshany, H., and Weltfriend, S. Allergic contact dermatitis caused by Salvia officinalis extract. Contact Dermatitis 2011;64(4):237-238. PubMed
  22. Halicioglu, O., Astarcioglu, G., Yaprak, I., and Aydinlioglu, H. Toxicity of Salvia officinalis in a newborn and a child: an alarming report. Pediatr.Neurol. 2011;45(4):259-260. PubMed
  23. Sertoli, A., Fabbri, P., Campolmi, P., and Panconesi, E. Allergic contact dermatitis to Salvia Officinalis, Inula Viscosa and Conyza Bonariensis. Contact Dermatitis 1978;4(5):314-315.
  24. Vandecasteele K, Ost P, Oosterlinck W, et al. Evaluation of the efficacy and safety of Salvia officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation. Phytother Res. 2012;26(2):208-13.
  25. Kianbakht S, Dabaghian FH. Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo. Controlled clinical trial. Complement Ther Med. 2013;21(5):441-6. PubMed
  26. Amini L, Mojab F, Jahanfar S, Sepidarkish M, Raoofi Z, Maleki-Hajiagha A. Efficacy of Salvia officinalis extract on the prevention of insulin resistance in euglycemic patients with polycystic ovary syndrome: A double-blinded placebo-controlled clinical tr
  27. Behradmanesh S, Derees F, Rafieian-Kopaei M. Effect of Salvia officinalis on diabetic patients. J Renal Inj Prev. 2013;2(2):51-4.

See these in context on the Sage monograph →

Clove 26 references
  1. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  2. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  3. Kanerva L, Estlander T, Jolanki R. Occupational allergic contact dermatitis from spices. Contact Dermatitis 1996;35:157-62. PubMed
  4. Chen SJ, Wang MH, Chen IJ. Antiplatelet and calcium inhibitory properties of eugenol and sodium eugenol acetate. Gen Pharmacol 1996;27:629-33. PubMed
  5. Malson JL, Lee EM, Murty R, et al. Clove cigarette smoking: biochemical, physiological, and subjective effects. Pharmacol Biochem Behav 2003;74:739-45. PubMed
  6. Kirsch CM, Yenokida GG, Jensen WA, et al. Non-cardiogenic pulmonary oedema due to the intravenous administration of clove oil. Thorax 1990;45:235-6. PubMed
  7. Pallares, D. E. Link between clove cigarettes and urticaria? Postgrad.Med 10-1-1999;106(4):153. PubMed
  8. Barnard, D. R. Repellency of essential oils to mosquitoes (Diptera: Culicidae). J Med Entomol. 1999;36(5):625-629. PubMed
  9. Sanchez-Perez, J. and Garcia-Diez, A. Occupational allergic contact dermatitis from eugenol, oil of cinnamon and oil of cloves in a physiotherapist. Contact Dermatitis 1999;41(6):346-347. PubMed
  10. Andersen, K. E., Johansen, J. D., Bruze, M., Frosch, P. J., Goossens, A., Lepoittevin, J. P., Rastogi, S., White, I., and Menne, T. The time-dose-response relationship for elicitation of contact dermatitis in isoeugenol allergic individuals. Toxicol.Appl PubMed
  11. Alqareer, A., Alyahya, A., and Andersson, L. The effect of clove and benzocaine versus placebo as topical anesthetics. J Dent 2006;34(10):747-750. PubMed
  12. Lane, B. W., Ellenhorn, M. J., Hulbert, T. V., and McCarron, M. Clove oil ingestion in an infant. Hum.Exp Toxicol. 1991;10(4):291-294. PubMed
  13. Quirce, S., Fernandez-Nieto, M., del, Pozo, V, Sastre, B., and Sastre, J. Occupational asthma and rhinitis caused by eugenol in a hairdresser. Allergy 2008;63(1):137-138. PubMed
  14. Srivastava, K. C. and Malhotra, N. Acetyl eugenol, a component of oil of cloves (Syzygium aromaticum L.) inhibits aggregation and alters arachidonic acid metabolism in human blood platelets. Prostaglandins Leukot.Essent.Fatty Acids 1991;42(1):73-81. PubMed
  15. Dyrbye, B. A., Dubois, L., Vink, R., and Horn, J. A patient with clove oil intoxication. Anaesth.Intensive Care 2012;40(2):365-366.
  16. Guidotti, T. L., Laing, L., and Prakash, U. B. Clove cigarettes. The basis for concern regarding health effects. West J Med 1989;151(2):220-228.
  17. Anonymous. Evaluation of the health hazard of clove cigarettes. Council on Scientific Affairs. JAMA 12-23-1988;260(24):3641-3644. DOI
  18. Romaguera, C., Alomar, A., Camarasa, J. M., Garcia, Bravo B., Garcia, Perez A., Grimalt, F., Guerra, P., Lopez, Gorretcher B., Pascual, A. M., Miranda, A., and . Contact dermatitis in children. Contact Dermatitis 1985;12(5):283-284. PubMed
  19. Hackett, P. H., Rodriguez, G., and Roach, R. C. Clove cigarettes and high-altitude pulmonary edema. JAMA 6-28-1985;253(24):3551-3552. DOI
  20. Isaacs, G. Permanent local anaesthesia and anhidrosis after clove oil spillage. Lancet 4-16-1983;1(8329):882. PubMed
  21. Saeed, S. A. and Gilani, A. H. Antithrombotic activity of clove oil. J Pak Med Assoc 1994;44(5):112-115.
  22. Hartnoll, G., Moore, D., and Douek, D. Near fatal ingestion of oil of cloves. Arch.Dis Child 1993;69(3):392-393. PubMed
  23. Srivastava, K. C. Antiplatelet principles from a food spice clove (Syzygium aromaticum L) [corrected]. Prostaglandins Leukot.Essent.Fatty Acids 1993;48(5):363-372.
  24. Jiang Q, Wu Y, Zhang H, et al. Development of essential oils as skin permeation enhancers: penetration enhancement effect and mechanism of action. Pharmaceutical Biol. 2017;55(1):1592-1600. PubMed
  25. Mohan R, Jose S, Mulakkal J, Karpinsky-Semper D, Swick AG, Krishnakumar IM. Water-soluble polyphenol-rich clove extract lowers pre- and post-prandial blood glucose levels in healthy and prediabetic volunteers: an open label pilot study. BMC Complement Alt PubMed
  26. Alharbi NFM, Ahad A, Bin Jardan YA, Al-Jenoobi FI. Effect of eugenol on cytochrome P450 1A2, 2C9, 2D6, and 3A4 activity in human liver microsomes. Saudi Pharm J 2024;32(7):102118. PubMed

See these in context on the Clove monograph →

Spearmint 20 references
  1. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  2. Akdogan M, Ozguner M, Aydin G, Gokalp O. Investigation of biochemical and histopathological effects of Mentha piperita Labiatae and Mentha spicata Labiatae on liver tissue in rats. Hum Exp Toxicol 2004;23:21-8.
  3. Poon, T. S. and Freeman, S. Cheilitis caused by contact allergy to anethole in spearmint flavoured toothpaste. Australas.J Dermatol. 2006;47(4):300-301. PubMed
  4. Andersen, K. E. Contact allergy to toothpaste flavors. Contact Dermatitis 1978;4(4):195-198. PubMed
  5. de Sousa, D. P., Farias Nobrega, F. F., and de Almeida, R. N. Influence of the chirality of (R)-(-)- and (S)-(+)-carvone in the central nervous system: a comparative study. Chirality 5-5-2007;19(4):264-268.
  6. Larsen, W., Nakayama, H., Fischer, T., Elsner, P., Frosch, P., Burrows, D., Jordan, W., Shaw, S., Wilkinson, J., Marks, J., Jr., Sugawara, M., Nethercott, M., and Nethercott, J. Fragrance contact dermatitis: a worldwide multicenter investigation (Part II PubMed
  7. Guney, M., Oral, B., Karahanli, N., Mungan, T., and Akdogan, M. The effect of Mentha spicata Labiatae on uterine tissue in rats. Toxicol.Ind.Health 2006;22(8):343-348.
  8. Masumoto, Y., Morinushi, T., Kawasaki, H., Ogura, T., and Takigawa, M. Effects of three principal constituents in chewing gum on electroencephalographic activity. Psychiatry Clin.Neurosci. 1999;53(1):17-23. PubMed
  9. Bulat, R., Fachnie, E., Chauhan, U., Chen, Y., and Tougas, G. Lack of effect of spearmint on lower oesophageal sphincter function and acid reflux in healthy volunteers. Aliment.Pharmacol Ther. 1999;13(6):805-812. PubMed
  10. Francalanci, S., Sertoli, A., Giorgini, S., Pigatto, P., Santucci, B., and Valsecchi, R. Multicentre study of allergic contact cheilitis from toothpastes. Contact Dermatitis 2000;43(4):216-222. PubMed
  11. Bonamonte, D., Mundo, L., Daddabbo, M., and Foti, C. Allergic contact dermatitis from Mentha spicata (spearmint). Contact Dermatitis 2001;45(5):298.
  12. Tomson, N., Murdoch, S., and Finch, T. M. The dangers of making mint sauce. Contact Dermatitis 2004;51(2):92-93. PubMed
  13. Clayton, R. and Orton, D. Contact allergy to spearmint oil in a patient with oral lichen planus. Contact Dermatitis 2004;51(5-6):314-315. PubMed
  14. Dal Sacco, D., Gibelli, D., and Gallo, R. Contact allergy in the burning mouth syndrome: a retrospective study on 38 patients. Acta Derm.Venereol. 2005;85(1):63-64. PubMed
  15. Goncalves, J. C., Oliveira, Fde S., Benedito, R. B., de Sousa, D. P., de Almeida, R. N., and de Araujo, D. A. Antinociceptive activity of (-)-carvone: evidence of association with decreased peripheral nerve excitability. Biol Pharm Bull. 2008;31(5):1017- PubMed
  16. Ormerod, A. D. and Main, R. A. Sensitisation to "sensitive teeth" toothpaste. Contact Dermatitis 1985;13(3):192-193. PubMed
  17. Skrebova, N., Brocks, K., and Karlsmark, T. Allergic contact cheilitis from spearmint oil. Contact Dermatitis 1998;39(1):35. PubMed
  18. Damiani E, Aloia AM, Priore MG, et al. Allergy to mint (Mentha spicata). J Investig Allergol Clin Immunol 2012;22:309-10.
  19. Connelly AE, Tucker AJ, Tulk H, et al. High-rosmarinic acid spearmint tea in the management of knee osteoarthritis symptoms. J Med Food 2014;17:1361-7. PubMed
  20. Lasrado JA, Nieman KM, Fonseca BA, et al. Safety and tolerability of a dried aqueous spearmint extract. Regul Toxicol Pharmacol 2017;86:167-176. PubMed

See these in context on the Spearmint monograph →

Myrrh 8 references
  1. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
  2. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  3. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  4. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  5. Al Faraj S. Antagonism of the anticoagulant effect of warfarin caused by the use of Commiphora molmol as a herbal medication: a case report. Ann Trop Med Parasitol 2005;99:219-20.
  6. Al-Jaroudi D, Kaddour O, Al-Amin N. Risks of myrrh use in pregnancy. JBRA Assist Reprod 2016;20(4):257-8.
  7. Xu YY, Li L, Xuan L, Guan K. Patch test diagnosis of non-immediate cutaneous reaction to myrrh following oral intake of a traditional Chinese medicine decoction. Contact Dermatitis. 2019;80(2):135-136. PubMed
  8. Al-Romaiyan A, Huang GC, Jones P, Persaud S. Commiphora myrrha stimulates insulin secretion from mouse and human islets of Langerhans. J Ethnopharmacol. 2021 Jan 10;264:113075. PubMed

See these in context on the Myrrh monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring